HELIX BIOPHARMA CORP. REPORTS VOTING RESULTS AND APPOINTMENT OF NEW BOARD DIRECTOR

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company’s annual and special meeting of shareholders held on January 28, 2022 (the “Meeting”). In aaccordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, and the appointment of Mr. Adam Uszpolewicz to Helix’s Board of Directors.

20220128 – HBP Press Release – Proxy Vote (FINAL)